Last reviewed · How we verify
NCT06334731
Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
trial in COVID-19 in 400 participants. Completed in 14 July 2025.
14 July 2025
Quick facts
| Lead sponsor | Methodist Health System |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 6 July 2021 |
| Primary completion | 14 July 2025 |
| Estimated completion | 14 July 2025 |
| Sites | 1 location across United States |
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Methodist Health System — full company profile →
Who can join
18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06334731
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Methodist Health System trials
Trials by the same sponsor.
- NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
- NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
- NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
- NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
- NCT07492758 — Management of Extremity Injuries Registry · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06334731 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
- Last refreshed: 28 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06334731.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing